KPIs & Operating Metrics(New)
Balance Sheet
Daily Values
Growth Metrics
Income Statement
Others
Receivables - NetReceivables - OtherReceivables Refunds
Ratios

Takeda Pharmaceutical (TAK) Accumulated Depreciation & Amortization (2018 - 2020)

Takeda Pharmaceutical (TAK) has 3 years of Accumulated Depreciation & Amortization data on record, last reported at $465.4 million in Q1 2020.

  • For Q1 2020, Accumulated Depreciation & Amortization rose 3452.99% year-over-year to $465.4 million; the TTM value through Mar 2020 reached $465.4 million, up 3452.99%, while the annual FY2020 figure was $466.2 million, 3483.09% up from the prior year.
  • Accumulated Depreciation & Amortization reached $465.4 million in Q1 2020 per TAK's latest filing, up from $13.1 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $465.4 million in Q1 2020 and bottomed at $13.1 million in Q1 2019.
  • Average Accumulated Depreciation & Amortization over 3 years is $204.4 million, with a median of $134.7 million recorded in 2018.
  • Peak YoY movement for Accumulated Depreciation & Amortization: crashed 90.28% in 2019, then skyrocketed 3452.99% in 2020.
  • A 3-year view of Accumulated Depreciation & Amortization shows it stood at $134.7 million in 2018, then plummeted by 90.28% to $13.1 million in 2019, then soared by 3452.99% to $465.4 million in 2020.
  • Per Business Quant database, its latest 3 readings for Accumulated Depreciation & Amortization were $465.4 million in Q1 2020, $13.1 million in Q1 2019, and $134.7 million in Q1 2018.